Efficacy And Safety Of Tralokinumab Monotherapy In North American Adult Patients With Moderate-To-Severe Atopic Dermatitis: A Subanalysis Of The Ecztra 2 Trial

Background: Two double-blinded, randomized, placebo-controlled, multinational, 52-week (wk) trials demonstrated efficacy and safety of tralokinumab monotherapy in moderate-to-severe atopic dermatitis (ECZTRA 1, ECZTRA 2). This subanalysis examined efficacy and safety outcomes in North American patients in the ECZTRA 2 trial. Type of study: Phase 3 subanalysis.